Gyre Therapeutics FY revenue rises 10.2% to $116.6M
Gyre Therapeutics (NASDAQ:GYRE) reported a year of strategic transformation and steady financial growth for the full year 2025, posting total revenue of $116.6 million, a 10.2% increase compared to the prior year.
The company ended the period with a solid liquidity position, reporting $75.9 million in cash and deposits as of December 31, 2025.
The centerpiece of the company's forward-looking strategy is a definitive agreement to acquire Cullgen for approximately $300 million.
The acquisition is expected to significantly broaden Gyre’s portfolio by integrating Cullgen’s targeted protein degradation platform, positioning the combined entity to address a wider range of unmet needs in fibrosis and inflammatory diseases.
On the clinical front, Gyre is nearing critical regulatory and data milestones.
The company confirmed it is on track to submit a New Drug Application (NDA) for Hydronidone for conditional approval in China during the first half of 2026.
Additionally, the firm has completed enrollment for its 52-week Phase 3 clinical trial of pirfenidone, which includes 272 patients, further strengthening its late-stage pipeline in the respiratory and fibrotic space.
Looking ahead, management issued 2026 revenue guidance in the range of $100.5 million to $111 million.
More from United States
Arm Q2 revenue hits $1.44B as AI chip demand surges
Qualcomm Q4 earnings beat estimates as auto sales jump 89%
Melco Resorts Q3 revenue falls 10% to $1.17 billion
Emerson Q4 revenue accelerates 7% to $5.2 billion
Flowco Q3 revenue revs up 46% to $258.6 million
Clear secure Q3 revenue hits $292.9M as top line expands 27.8%
